TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25583139

Group type: EXPERIMENTAL
Intervention: Favorable psychosocial factors in youth
Number of subjects: 1089

Group type: EXPERIMENTAL
Intervention: Favorable socioeconomic environment
Number of subjects: 1089

Group type: EXPERIMENTAL
Intervention: Participants' self‐regulatory behavior
Number of subjects: 1089
Study: 24083628

Group type: EXPERIMENTAL
Intervention: Nonspecific mandibular mobilization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific mandibular mobilization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Facial massage therapy
Number of subjects: 0
Study: 21474806

Group type: EXPERIMENTAL
Intervention: Stroke unit care with early supported discharge (ESD)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Ordinary stroke unit care
Number of subjects: 320
Study: 19488741

Group type: EXPERIMENTAL
Intervention: Nicotine (14 mg for smokers, 7 mg for nonsmokers)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 16437281

Group type: COMPARATOR
Intervention: Heller myotomy
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Heller myotomy plus Dor fundoplication
Number of subjects: 43
Study: 12527540

Group type: EXPERIMENTAL
Intervention: Cognitive/Behavioral Therapy-Alone (C/B-Alone)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Combined (C/B-Alone + Desipramine)
Number of subjects: 63
Study: 10706565

Group type: COMPARATOR
Intervention: IFN‐alpha2b 3 MU 3 times per week for 6 months
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Iron reduction before and during IFN‐alpha2b 3 MU 3 times per week for 6 months
Number of subjects: 82
Study: 9345325

Group type: EXPERIMENTAL
Intervention: HFX/PE (Hyperfractionated radiation therapy with concurrent chemotherapy)
Number of subjects: 279

Group type: COMPARATOR
Intervention: HFX (Hyperfractionated radiation therapy alone)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: HFX/PE
Number of subjects: 279

Group type: COMPARATOR
Intervention: HFX
Number of subjects: 279
Study: 8456469

Group type: EXPERIMENTAL
Intervention: 15-deoxyspergualin
Number of subjects: 25

Group type: COMPARATOR
Intervention: OKT3
Number of subjects: 25
Study: 3954817

Group type: EXPERIMENTAL
Intervention: Drugs from 7 psychopharmacological classes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Static pupillometry
Number of subjects: 0
Study: 31234234

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist intervention via home medication management review (HMMR)
Number of subjects: 158
Study: 27020070

Group type: EXPERIMENTAL
Intervention: Oxytocin treatment (placebo)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Serotonin treatment (placebo)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 77
Study: 23937692

Group type: EXPERIMENTAL
Intervention: Gaze cues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Symbolic cues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional connectivity analysis during gaze cueing
Number of subjects: 0
Study: 22781571

Group type: EXPERIMENTAL
Intervention: Endo‐A‐CAB (minimally invasive technique)
Number of subjects: 194

Group type: COMPARATOR
Intervention: sternotomy OPCAB (control group)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 194
Study: 21092445

Group type: EXPERIMENTAL
Intervention: Early intervention (coronary angiography < 24 hours after randomization)
Number of subjects: 814

Group type: COMPARATOR
Intervention: Delayed intervention (coronary angiography > 36 hours after randomization)
Number of subjects: 814
Study: 18756476

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 447

Group type: COMPARATOR
Intervention: Lamotrigine
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Valproate (age < 26 years)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Lamotrigine (age < 26 years)
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Valproate (age ≥ 26 years)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Lamotrigine (age ≥ 26 years)
Number of subjects: 447
Study: 16089270

Group type: EXPERIMENTAL
Intervention: Euglycemic clamp (CI)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo clamp (PI)
Number of subjects: 9
Study: 12091998

Group type: COMPARATOR
Intervention: Primary sinus surgery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Revision sinus surgery
Number of subjects: 40
Study: 10519625

Group type: EXPERIMENTAL
Intervention: One direct current electrical pulse at 1.36‐1.50 kV/cm for 40‐60 micros (group 1)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Three pulses every 15‐20 minutes (group 2)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Treated the same as group 2 but with no electrical stimulation (group 3)
Number of subjects: 104
Study: 8620707

Group type: EXPERIMENTAL
Intervention: Hospital-based outpatient pulmonary rehabilitation program (HRP)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Home-care rehabilitation program (HCRP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No rehabilitation therapy (Control group)
Number of subjects: 45
Study: 2011430

Group type: EXPERIMENTAL
Intervention: Methylphenidate 5 mg twice a day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Methylphenidate 10 mg twice a day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Methylphenidate 15 mg twice a day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Moderate to high dose of methylphenidate
Number of subjects: 40
Study: 6796288

Group type: EXPERIMENTAL
Intervention: Lidoflazine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 30053298

Group type: EXPERIMENTAL
Intervention: Oral sodium bicarbonate supplementation to maintain venous bicarbonate levels at 24-26 mEq/L along with standard care as per KDIGO 2012 guidelines
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group received standard care alone
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Intervention arm with oral sodium bicarbonate supplementation
Number of subjects: 188
Study: 29893957

Group type: EXPERIMENTAL
Intervention: Preemptive cidofovir
Number of subjects: 572

Group type: COMPARATOR
Intervention: Allogeneic HCT recipients with HAdV infection
Number of subjects: 572
Study: 27779764

Group type: EXPERIMENTAL
Intervention: SF-36 Physical Function
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: SF-36 Role Physical
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: SF-36 Bodily Pain
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: SF-36 Physical Component Summary
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: SF-36 Mental Health
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: SF-36 Mental Component Summary
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: HADS anxiety score
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: HADS depression score
Number of subjects: 137
Study: 25557016

Group type: EXPERIMENTAL
Intervention: LL group (full left-lateral position)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: LS group (initially full left-lateral, then left-tilt supine)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: CS group (initially full left-lateral, then left-tilt supine with needle oriented cephalad)
Number of subjects: 99
Study: 23218506

Group type: EXPERIMENTAL
Intervention: Platelet-Rich-Fibrin (PRF)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Conventional collagen membrane (Bio-Gide(®))
Number of subjects: 6
Study: 21812968

Group type: EXPERIMENTAL
Intervention: Edinburgh Postnatal Depression Scale (EPDS)
Number of subjects: 4150

Group type: EXPERIMENTAL
Intervention: Randomised trial (n = 253)
Number of subjects: 4150

Group type: EXPERIMENTAL
Intervention: EPDS question 10 endorsement
Number of subjects: 4150

Group type: EXPERIMENTAL
Intervention: Follow-up at 18 weeks
Number of subjects: 4150
Study: 19538185

Group type: EXPERIMENTAL
Intervention: UVB irradiation with a suberythematogenic regimen
Number of subjects: 77

Group type: COMPARATOR
Intervention: UVB irradiation with an erythematogenic regimen
Number of subjects: 77
Study: 15861492

Group type: EXPERIMENTAL
Intervention: Acupuncture on anti-smoking acupoints of the ear (case group)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Acupuncture at other sites of the ear (control group)
Number of subjects: 238
Study: 15916412

Group type: EXPERIMENTAL
Intervention: Glasgow Outcome Scale (GOS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eight-point expanded scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surrogate outcome measures (magnetic resonance imaging, neurochemical, neuropsychological, quality of life measures)
Number of subjects: 0
Study: 10621984

Group type: EXPERIMENTAL
Intervention: Practice-based educational visits encouraging exploration of barriers to change
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no encouragement to explore barriers)
Number of subjects: 18
Study: 8610232

Group type: EXPERIMENTAL
Intervention: Vinorelbine (single agent)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vindesine/Cisplatin (combination)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vinorelbine/Cisplatin (combination)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-Fluorouracil and Leucovorin (control)
Number of subjects: 0
Study: 1821699

Group type: EXPERIMENTAL
Intervention: Total sleep deprivation (TSD)
Number of subjects: 0
Study: 7044797

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg t.i.d.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Benoxaprofen 600 mg once daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Benoxaprofen
Number of subjects: 40
Study: 31668476

Group type: EXPERIMENTAL
Intervention: Real-time functional magnetic resonance imaging neurofeedback from the SMA
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 21
Study: 30842118

Group type: EXPERIMENTAL
Intervention: Post-traumatic stress disorder (PTSD)
Number of subjects: 1032
Study: 29084790

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention with tailored telephone consultations, varying in intensity and follow-up frequency.
Number of subjects: 6000
Study: 25483598

Group type: EXPERIMENTAL
Intervention: Budesonide transnasal nebulization
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 23983157

Group type: COMPARATOR
Intervention: Traditional retention strategy - mailed reminder letters (referent category)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Traditional retention strategy - telephone number redials
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Nontraditional retention strategy - Facebook outreach
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Nontraditional retention strategy - school administration assistance
Number of subjects: 422
Study: 21852503

Group type: EXPERIMENTAL
Intervention: My Teaching Partner‐Secondary; a Web‐mediated approach focused on improving teacher-student interactions.
Number of subjects: 2237
Study: 20068404

Group type: EXPERIMENTAL
Intervention: Ofatumumab
Number of subjects: 0
Study: 17601444

Group type: EXPERIMENTAL
Intervention: Ketorolac 0.4% (Acular LS)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Nepafenac 0.1% (Nevanac)
Number of subjects: 132
Study: 15226663

Group type: EXPERIMENTAL
Intervention: e-AGV group (AGV implant surgery using pericardial membrane)
Number of subjects: 20

Group type: COMPARATOR
Intervention: AGV group (AGV implant surgery without surface area extension)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: e-AGV group
Number of subjects: 20

Group type: COMPARATOR
Intervention: AGV group
Number of subjects: 20
Study: 12190806

Group type: COMPARATOR
Intervention: Normal saline (NS) 2 ml i.v.
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg in 2 ml NS with venous occlusion (VO) for 30 s
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg in 2 ml NS with venous occlusion (VO) for 60 s
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg in 2 ml NS with venous occlusion (VO) for 120 s
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ketorolac 15 mg in 2 ml NS with propofol injection after 60 s
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg in 2 ml NS with propofol injection after 60 s
Number of subjects: 180
Study: 9694611

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 20 mg/day for 2 years (postmenopausal)
Number of subjects: 1579

Group type: EXPERIMENTAL
Intervention: Chemotherapy (MMC + CPA)
Number of subjects: 1579

Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy (TAM + MMC + CPA)
Number of subjects: 1579

Group type: COMPARATOR
Intervention: Tamoxifen (TAM)
Number of subjects: 1579
Study: 7653695

Group type: EXPERIMENTAL
Intervention: Sodium lactate infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 20
Study: 2527044

Group type: EXPERIMENTAL
Intervention: Amlodipine (2.5 to 10.0 mg/d) in combination with HCTZ (50 mg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: HCTZ (50 mg/d) with placebo
Number of subjects: 20
Study: 799977

Group type: EXPERIMENTAL
Intervention: Burinex K
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lasix+K
Number of subjects: 60
Study: 31802278

Group type: EXPERIMENTAL
Intervention: Irrigation fluid at body temperature (37 °C, BT-group)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Irrigation fluid at room temperature (22 °C, RT-group)
Number of subjects: 172
Study: 31267613

Group type: EXPERIMENTAL
Intervention: MAMIR
Number of subjects: 60
Study: 28536206

Group type: EXPERIMENTAL
Intervention: 200 mg/kg dextrose gel
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 25984891

Group type: EXPERIMENTAL
Intervention: LBPP treadmill
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control treadmill
Number of subjects: 11
Study: 23908163

Group type: EXPERIMENTAL
Intervention: ADD (feed additives including chelated minerals, organic Se, yeast culture, direct-fed microbials, and Yucca schidigera extract)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ADD
Number of subjects: 20

Group type: COMPARATOR
Intervention: CTRL (control group without additives)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CTRL
Number of subjects: 20
Study: 21571345

Group type: EXPERIMENTAL
Intervention: Silodosin 4 mg
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 17999976

Group type: EXPERIMENTAL
Intervention: Single intravenous dose of 600 mg linezolid
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Twice-daily administration of linezolid (extrapolated)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (historic data from healthy volunteers)
Number of subjects: 24
Study: 15713524

Group type: COMPARATOR
Intervention: Gemcitabine 1000 mg/m2 on days 1, 8, 15, every 28 days (arm Q4W)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1125 mg/m2 on days 1 and 8, every 21 days (arm Q3W)
Number of subjects: 81
Study: 11943073

Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac sodium
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9794735

Group type: EXPERIMENTAL
Intervention: Lacidipine (calcium antagonist)
Number of subjects: 2259

Group type: COMPARATOR
Intervention: Atenolol (beta-blocker)
Number of subjects: 2259
Study: 9097789

Group type: EXPERIMENTAL
Intervention: Immediate prophylactic panretinal photocoagulation (PRP)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Close observation (control group)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: PRP treatment after TC‐INV/ANV developed
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: PRP treatment after TC‐INV/ANV developed (previously treated eyes)
Number of subjects: 181
Study: 2669938

Group type: COMPARATOR
Intervention: Bromovinyldeoxyuridine (BVDU) + placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Bromovinyldeoxyuridine (BVDU) + 1.5 X 10(6) IU recombinant a 2C interferon
Number of subjects: 22
Study: 31512365

Group type: EXPERIMENTAL
Intervention: metformin plus lifestyle intervention (LSI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: lifestyle intervention (LSI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: metformin 850 mg once daily for the first 2 weeks, then twice daily thereafter
Number of subjects: 0
Study: 29362047

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.2 mcg/kg/hour)
Number of subjects: 82
Study: 27978912

Group type: EXPERIMENTAL
Intervention: Periodontal treatment using periodontal endoscope
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional treatment method (control group)
Number of subjects: 11
Study: 25027286

Group type: EXPERIMENTAL
Intervention: 20 mg rabeprazole
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 22739747

Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy (AIT)
Number of subjects: 50
Study: 20697905

Group type: EXPERIMENTAL
Intervention: Water environment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Dry land environment
Number of subjects: 9
Study: 19001830

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 101

Group type: COMPARATOR
Intervention: Calcium acetate
Number of subjects: 101
Study: 15926439

Group type: EXPERIMENTAL
Intervention: Twin-block appliance
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 12011683

Group type: EXPERIMENTAL
Intervention: Surgical treatment with cytokine adjuvants, peeling of the internal limiting membrane, vital staining with indocyanine green dye, variations in postoperative face-down positioning
Number of subjects: 0
Study: 9642895

Group type: EXPERIMENTAL
Intervention: Interpretive therapy
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Supportive therapy
Number of subjects: 144

Group type: COMPARATOR
Intervention: Both forms of therapy
Number of subjects: 144
Study: 8124800

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg)
Number of subjects: 288
Study: 2811412

Group type: EXPERIMENTAL
Intervention: Arterial pH adjusted in a randomized order (high to low or low to high) in group I patients during hypothermic cardiopulmonary bypass.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Constant arterial pH during stable hypothermia in group II patients.
Number of subjects: 50
Study: 1217691

Group type: EXPERIMENTAL
Intervention: Salicylates (Colfarit)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No antithrombotic medications (Control)
Number of subjects: 50
Study: 31822203

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 49
Study: 30892806

Group type: EXPERIMENTAL
Intervention: Digitoxin (target serum concentration 8-18 ng/mL)
Number of subjects: 2190

Group type: COMPARATOR
Intervention: Standard of care treatment
Number of subjects: 2190
Study: 28224950

Group type: EXPERIMENTAL
Intervention: Injection-site splinting (experimental group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No injection-site splinting (control group)
Number of subjects: 60
Study: 26027223

Group type: EXPERIMENTAL
Intervention: Reamberin 1.5% (succinate‐containing infusion solution)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 87
Study: 23088195

Group type: EXPERIMENTAL
Intervention: Retrieval strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective attention strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strategy confidence and perceived strategy difficulty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived speed of responses
Number of subjects: 0
Study: 21422859

Group type: EXPERIMENTAL
Intervention: Cefazolin 2 g administered 30-60 minutes before skin incision
Number of subjects: 29
Study: 20039532

Group type: EXPERIMENTAL
Intervention: Psycho-educational Internet self-help tool
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study: 17024647

Group type: EXPERIMENTAL
Intervention: LHTL group (living high-training low)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: LHTL group
Number of subjects: 16
Study: 15127162

Group type: EXPERIMENTAL
Intervention: Thêta-Cream
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bepanthol lotion
Number of subjects: 20
Study: 11388099

Group type: EXPERIMENTAL
Intervention: Atrial undersensing < 5% (group 1)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Atrial undersensing 5%-10% (group 2)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Atrial undersensing > 10% (group 3)
Number of subjects: 21
Study: 9915106

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Basal (no drug administration)
Number of subjects: 7
Study: 7708266

Group type: EXPERIMENTAL
Intervention: sTNF-R measurement in patients undergoing kidney graft
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: sTNF-R measurement in longstanding recipients
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: sTNF-R measurement during graft rejection
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: sTNF-R/SCr levels
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: sIl2-R measurement
Number of subjects: 136
Study: 30613020

Group type: EXPERIMENTAL
Intervention: Propofol sedation (loading dose of 0.6 mg·kg‐1·h‐1 followed by maintenance dose of 3 mg·kg‐1·h‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 60
Study: 27745552

Group type: EXPERIMENTAL
Intervention: Clinic follow-up at 2 weeks
Number of subjects: 731

Group type: COMPARATOR
Intervention: Home-assessment at 2 weeks
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Clinic follow-up at 3 months
Number of subjects: 731

Group type: COMPARATOR
Intervention: Home-assessment at 3 months
Number of subjects: 731
Study: 24785921

Group type: EXPERIMENTAL
Intervention: Conventional brackets
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Active self‐ligating brackets
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Passive self‐ligating brackets
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All bracket types
Number of subjects: 100